Oak Tree Capital Management, led by Howard Marks, has fully divested its stake in Sarepta Therapeutics Inc. The hedge fund's previous filing indicated a holding in Sarepta Therapeutics valued at approximately $30.82 billion.
This exit represents a significant shift in Oak Tree Capital's portfolio, which currently comprises 240 holdings with a total reported value of over $19.33 trillion. The complete removal of Sarepta Therapeutics from its holdings could signal a change in the fund's outlook for the biotechnology company.
The reasons behind Oak Tree Capital's decision to exit the position were not disclosed. Investors often look to such portfolio adjustments for insights into institutional sentiment, though specific motivations for divestment can vary widely.